Guardant Health, Inc.
Guardant Health, Inc. GH Peers
See (GH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GH | $48.06 | -0.72% | 6B | -14.18 | -$3.39 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.58% |
| TMO | $401.89 | +0.89% | 151.7B | 23.59 | $17.04 | +0.40% |
| DHR | $196.04 | +2.02% | 140.3B | 37.92 | $5.17 | +0.58% |
| IDXX | $524.91 | +0.52% | 42.2B | 48.47 | $10.83 | N/A |
| A | $115.76 | +1.60% | 32.9B | 28.51 | $4.06 | +0.84% |
| IQV | $152.29 | +3.34% | 26.3B | 20.80 | $7.32 | N/A |
| MTD | $1,183.57 | +1.63% | 24.6B | 29.58 | $40.01 | N/A |
| NTRA | $163.76 | -1.06% | 22.4B | -111.40 | -$1.47 | N/A |
| WAT | $351.02 | +1.35% | 20.9B | 31.88 | $11.01 | N/A |
Stock Comparison
GH vs DHR-PB Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GH is priced at $48.06, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GH's ROE is +3.69%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs TMO Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, TMO has a market cap of 151.7B. Regarding current trading prices, GH is priced at $48.06, while TMO trades at $401.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas TMO's P/E ratio is 23.59. In terms of profitability, GH's ROE is +3.69%, compared to TMO's ROE of +0.13%. Regarding short-term risk, GH is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs DHR Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, DHR has a market cap of 140.3B. Regarding current trading prices, GH is priced at $48.06, while DHR trades at $196.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas DHR's P/E ratio is 37.92. In terms of profitability, GH's ROE is +3.69%, compared to DHR's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs IDXX Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, IDXX has a market cap of 42.2B. Regarding current trading prices, GH is priced at $48.06, while IDXX trades at $524.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas IDXX's P/E ratio is 48.47. In terms of profitability, GH's ROE is +3.69%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, GH is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs A Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, A has a market cap of 32.9B. Regarding current trading prices, GH is priced at $48.06, while A trades at $115.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas A's P/E ratio is 28.51. In terms of profitability, GH's ROE is +3.69%, compared to A's ROE of +0.19%. Regarding short-term risk, GH is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs IQV Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, IQV has a market cap of 26.3B. Regarding current trading prices, GH is priced at $48.06, while IQV trades at $152.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas IQV's P/E ratio is 20.80. In terms of profitability, GH's ROE is +3.69%, compared to IQV's ROE of +0.21%. Regarding short-term risk, GH is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs MTD Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, MTD has a market cap of 24.6B. Regarding current trading prices, GH is priced at $48.06, while MTD trades at $1,183.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas MTD's P/E ratio is 29.58. In terms of profitability, GH's ROE is +3.69%, compared to MTD's ROE of +1.21%. Regarding short-term risk, GH is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs NTRA Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, NTRA has a market cap of 22.4B. Regarding current trading prices, GH is priced at $48.06, while NTRA trades at $163.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas NTRA's P/E ratio is -111.40. In terms of profitability, GH's ROE is +3.69%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, GH is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs WAT Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, WAT has a market cap of 20.9B. Regarding current trading prices, GH is priced at $48.06, while WAT trades at $351.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas WAT's P/E ratio is 31.88. In terms of profitability, GH's ROE is +3.69%, compared to WAT's ROE of +0.39%. Regarding short-term risk, GH is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs DGX Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, DGX has a market cap of 19.5B. Regarding current trading prices, GH is priced at $48.06, while DGX trades at $174.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas DGX's P/E ratio is 22.01. In terms of profitability, GH's ROE is +3.69%, compared to DGX's ROE of +0.13%. Regarding short-term risk, GH is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs PKI Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GH is priced at $48.06, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas PKI's P/E ratio is 41.45. In terms of profitability, GH's ROE is +3.69%, compared to PKI's ROE of +0.04%. Regarding short-term risk, GH is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs ILMN Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, ILMN has a market cap of 13.1B. Regarding current trading prices, GH is priced at $48.06, while ILMN trades at $82.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas ILMN's P/E ratio is -13.60. In terms of profitability, GH's ROE is +3.69%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, GH is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs ICLR Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, ICLR has a market cap of 11.2B. Regarding current trading prices, GH is priced at $48.06, while ICLR trades at $139.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas ICLR's P/E ratio is 15.15. In terms of profitability, GH's ROE is +3.69%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs RVTY Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, RVTY has a market cap of 10.8B. Regarding current trading prices, GH is priced at $48.06, while RVTY trades at $91.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas RVTY's P/E ratio is 38.00. In terms of profitability, GH's ROE is +3.69%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, GH is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs TEM Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, TEM has a market cap of 10.4B. Regarding current trading prices, GH is priced at $48.06, while TEM trades at $62.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas TEM's P/E ratio is -12.02. In terms of profitability, GH's ROE is +3.69%, compared to TEM's ROE of -5.31%. Regarding short-term risk, GH is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs EXAS Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, EXAS has a market cap of 10.4B. Regarding current trading prices, GH is priced at $48.06, while EXAS trades at $54.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas EXAS's P/E ratio is -9.92. In terms of profitability, GH's ROE is +3.69%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, GH is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs QGEN Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, QGEN has a market cap of 9.8B. Regarding current trading prices, GH is priced at $48.06, while QGEN trades at $45.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas QGEN's P/E ratio is 105.70. In terms of profitability, GH's ROE is +3.69%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, GH is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs MEDP Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, MEDP has a market cap of 8.5B. Regarding current trading prices, GH is priced at $48.06, while MEDP trades at $296.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas MEDP's P/E ratio is 22.14. In terms of profitability, GH's ROE is +3.69%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, GH is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs CRL Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, CRL has a market cap of 7.1B. Regarding current trading prices, GH is priced at $48.06, while CRL trades at $144.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas CRL's P/E ratio is -237.23. In terms of profitability, GH's ROE is +3.69%, compared to CRL's ROE of -0.01%. Regarding short-term risk, GH is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs SYNH Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GH is priced at $48.06, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GH's ROE is +3.69%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs RDNT Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, RDNT has a market cap of 4.4B. Regarding current trading prices, GH is priced at $48.06, while RDNT trades at $58.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas RDNT's P/E ratio is -136.40. In terms of profitability, GH's ROE is +3.69%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, GH is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs SHC Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, SHC has a market cap of 3.5B. Regarding current trading prices, GH is priced at $48.06, while SHC trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas SHC's P/E ratio is 136.67. In terms of profitability, GH's ROE is +3.69%, compared to SHC's ROE of +0.06%. Regarding short-term risk, GH is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs OLK Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GH is priced at $48.06, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas OLK's P/E ratio is -96.59. In terms of profitability, GH's ROE is +3.69%, compared to OLK's ROE of -0.05%. Regarding short-term risk, GH is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs TWST Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, TWST has a market cap of 1.9B. Regarding current trading prices, GH is priced at $48.06, while TWST trades at $31.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas TWST's P/E ratio is -9.71. In terms of profitability, GH's ROE is +3.69%, compared to TWST's ROE of -0.41%. Regarding short-term risk, GH is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs VIVO Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, GH is priced at $48.06, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas VIVO's P/E ratio is 21.09. In terms of profitability, GH's ROE is +3.69%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, GH is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs GRAL Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, GRAL has a market cap of 1.4B. Regarding current trading prices, GH is priced at $48.06, while GRAL trades at $38.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas GRAL's P/E ratio is -0.65. In terms of profitability, GH's ROE is +3.69%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, GH is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs NEOG Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, NEOG has a market cap of 1.1B. Regarding current trading prices, GH is priced at $48.06, while NEOG trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas NEOG's P/E ratio is -2.34. In terms of profitability, GH's ROE is +3.69%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, GH is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs CDNA Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, CDNA has a market cap of 1.1B. Regarding current trading prices, GH is priced at $48.06, while CDNA trades at $19.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas CDNA's P/E ratio is 17.43. In terms of profitability, GH's ROE is +3.69%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, GH is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs OPK Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, GH is priced at $48.06, while OPK trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas OPK's P/E ratio is -22.67. In terms of profitability, GH's ROE is +3.69%, compared to OPK's ROE of -0.03%. Regarding short-term risk, GH is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs FLGT Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, FLGT has a market cap of 652.4M. Regarding current trading prices, GH is priced at $48.06, while FLGT trades at $21.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas FLGT's P/E ratio is -16.11. In terms of profitability, GH's ROE is +3.69%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, GH is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs GRALV Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, GH is priced at $48.06, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas GRALV's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to GRALV's ROE of N/A. Regarding short-term risk, GH is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs CSTL Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, CSTL has a market cap of 508.2M. Regarding current trading prices, GH is priced at $48.06, while CSTL trades at $17.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas CSTL's P/E ratio is -92.63. In terms of profitability, GH's ROE is +3.69%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, GH is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs MYGN Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, MYGN has a market cap of 469.2M. Regarding current trading prices, GH is priced at $48.06, while MYGN trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas MYGN's P/E ratio is -4.54. In terms of profitability, GH's ROE is +3.69%, compared to MYGN's ROE of -0.15%. Regarding short-term risk, GH is more volatile compared to MYGN. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs PSNL Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, PSNL has a market cap of 460.8M. Regarding current trading prices, GH is priced at $48.06, while PSNL trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas PSNL's P/E ratio is -4.04. In terms of profitability, GH's ROE is +3.69%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, GH is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs LAB Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, LAB has a market cap of 402.6M. Regarding current trading prices, GH is priced at $48.06, while LAB trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas LAB's P/E ratio is -3.31. In terms of profitability, GH's ROE is +3.69%, compared to LAB's ROE of -0.28%. Regarding short-term risk, GH is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs CO Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GH is priced at $48.06, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas CO's P/E ratio is 5.06. In terms of profitability, GH's ROE is +3.69%, compared to CO's ROE of +0.11%. Regarding short-term risk, GH is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs FLDM Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GH is priced at $48.06, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GH's ROE is +3.69%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, GH is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs STIM Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, STIM has a market cap of 244.9M. Regarding current trading prices, GH is priced at $48.06, while STIM trades at $3.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas STIM's P/E ratio is -2.82. In terms of profitability, GH's ROE is +3.69%, compared to STIM's ROE of -2.09%. Regarding short-term risk, GH is more volatile compared to STIM. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs NEO Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, NEO has a market cap of 190.9M. Regarding current trading prices, GH is priced at $48.06, while NEO trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas NEO's P/E ratio is -12.16. In terms of profitability, GH's ROE is +3.69%, compared to NEO's ROE of -0.09%. Regarding short-term risk, GH is more volatile compared to NEO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs ACRS Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, ACRS has a market cap of 165.7M. Regarding current trading prices, GH is priced at $48.06, while ACRS trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas ACRS's P/E ratio is -0.96. In terms of profitability, GH's ROE is +3.69%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, GH is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs XGN Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, XGN has a market cap of 158.4M. Regarding current trading prices, GH is priced at $48.06, while XGN trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas XGN's P/E ratio is -8.63. In terms of profitability, GH's ROE is +3.69%, compared to XGN's ROE of -1.34%. Regarding short-term risk, GH is more volatile compared to XGN. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs ATLN Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, ATLN has a market cap of 140.7M. Regarding current trading prices, GH is priced at $48.06, while ATLN trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas ATLN's P/E ratio is -0.65. In terms of profitability, GH's ROE is +3.69%, compared to ATLN's ROE of -19.68%. Regarding short-term risk, GH is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs GTH Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GH is priced at $48.06, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas GTH's P/E ratio is -1.11. In terms of profitability, GH's ROE is +3.69%, compared to GTH's ROE of -1.01%. Regarding short-term risk, GH is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs GENE Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, GH is priced at $48.06, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas GENE's P/E ratio is -38.25. In terms of profitability, GH's ROE is +3.69%, compared to GENE's ROE of -3.62%. Regarding short-term risk, GH is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs PRE Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, PRE has a market cap of 106.6M. Regarding current trading prices, GH is priced at $48.06, while PRE trades at $8.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas PRE's P/E ratio is -2.42. In terms of profitability, GH's ROE is +3.69%, compared to PRE's ROE of -0.25%. Regarding short-term risk, GH is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs PRENW Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, PRENW has a market cap of 104.9M. Regarding current trading prices, GH is priced at $48.06, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas PRENW's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to PRENW's ROE of -0.25%. Regarding short-term risk, GH is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs MDXH Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, MDXH has a market cap of 102.5M. Regarding current trading prices, GH is priced at $48.06, while MDXH trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas MDXH's P/E ratio is -1.99. In terms of profitability, GH's ROE is +3.69%, compared to MDXH's ROE of -6.91%. Regarding short-term risk, GH is more volatile compared to MDXH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs NOTV Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, NOTV has a market cap of 92.4M. Regarding current trading prices, GH is priced at $48.06, while NOTV trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas NOTV's P/E ratio is -0.86. In terms of profitability, GH's ROE is +3.69%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, GH is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs VNRX Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, VNRX has a market cap of 59.5M. Regarding current trading prices, GH is priced at $48.06, while VNRX trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas VNRX's P/E ratio is -2.14. In terms of profitability, GH's ROE is +3.69%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, GH is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs SERA Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, SERA has a market cap of 56.9M. Regarding current trading prices, GH is priced at $48.06, while SERA trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas SERA's P/E ratio is -1.65. In terms of profitability, GH's ROE is +3.69%, compared to SERA's ROE of -0.51%. Regarding short-term risk, GH is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs OPGN Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, OPGN has a market cap of 46.3M. Regarding current trading prices, GH is priced at $48.06, while OPGN trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas OPGN's P/E ratio is -0.30. In terms of profitability, GH's ROE is +3.69%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, GH is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs BDSX Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, BDSX has a market cap of 44.4M. Regarding current trading prices, GH is priced at $48.06, while BDSX trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas BDSX's P/E ratio is -1.16. In terms of profitability, GH's ROE is +3.69%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, GH is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs DRIO Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, DRIO has a market cap of 31.2M. Regarding current trading prices, GH is priced at $48.06, while DRIO trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas DRIO's P/E ratio is -1.27. In terms of profitability, GH's ROE is +3.69%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, GH is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs STRRP Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, STRRP has a market cap of 30.2M. Regarding current trading prices, GH is priced at $48.06, while STRRP trades at $9.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas STRRP's P/E ratio is -4.71. In terms of profitability, GH's ROE is +3.69%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, GH is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs AKU Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GH is priced at $48.06, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas AKU's P/E ratio is -0.13. In terms of profitability, GH's ROE is +3.69%, compared to AKU's ROE of -5.32%. Regarding short-term risk, GH is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs ADVB Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, ADVB has a market cap of 20.3M. Regarding current trading prices, GH is priced at $48.06, while ADVB trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas ADVB's P/E ratio is -5.87. In terms of profitability, GH's ROE is +3.69%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, GH is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs PRPO Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, PRPO has a market cap of 16.9M. Regarding current trading prices, GH is priced at $48.06, while PRPO trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas PRPO's P/E ratio is -5.44. In terms of profitability, GH's ROE is +3.69%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, GH is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs CEMI Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GH is priced at $48.06, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GH's ROE is +3.69%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GH is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs ENZ Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GH is priced at $48.06, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GH's ROE is +3.69%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, GH is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs PMD Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, GH is priced at $48.06, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas PMD's P/E ratio is -5.24. In terms of profitability, GH's ROE is +3.69%, compared to PMD's ROE of -0.33%. Regarding short-term risk, GH is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs ME Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, GH is priced at $48.06, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas ME's P/E ratio is -0.03. In terms of profitability, GH's ROE is +3.69%, compared to ME's ROE of -3.10%. Regarding short-term risk, GH is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs BNGO Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, BNGO has a market cap of 12.6M. Regarding current trading prices, GH is priced at $48.06, while BNGO trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas BNGO's P/E ratio is -0.07. In terms of profitability, GH's ROE is +3.69%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, GH is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs TRIB Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, TRIB has a market cap of 12.1M. Regarding current trading prices, GH is priced at $48.06, while TRIB trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas TRIB's P/E ratio is -0.36. In terms of profitability, GH's ROE is +3.69%, compared to TRIB's ROE of +0.79%. Regarding short-term risk, GH is more volatile compared to TRIB. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs INBS Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, INBS has a market cap of 11.4M. Regarding current trading prices, GH is priced at $48.06, while INBS trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas INBS's P/E ratio is -1.25. In terms of profitability, GH's ROE is +3.69%, compared to INBS's ROE of -1.72%. Regarding short-term risk, GH is more volatile compared to INBS. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs CNTG Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GH is priced at $48.06, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GH's ROE is +3.69%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GH is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs BIAFW Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, BIAFW has a market cap of 8.2M. Regarding current trading prices, GH is priced at $48.06, while BIAFW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas BIAFW's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, GH is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs BIAF Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, BIAF has a market cap of 8.1M. Regarding current trading prices, GH is priced at $48.06, while BIAF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas BIAF's P/E ratio is -0.40. In terms of profitability, GH's ROE is +3.69%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, GH is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs MYNZ Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, MYNZ has a market cap of 7.9M. Regarding current trading prices, GH is priced at $48.06, while MYNZ trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas MYNZ's P/E ratio is -0.09. In terms of profitability, GH's ROE is +3.69%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, GH is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs STRR Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, STRR has a market cap of 6.8M. Regarding current trading prices, GH is priced at $48.06, while STRR trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas STRR's P/E ratio is -0.71. In terms of profitability, GH's ROE is +3.69%, compared to STRR's ROE of -0.24%. Regarding short-term risk, GH is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs BGLC Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, BGLC has a market cap of 5.6M. Regarding current trading prices, GH is priced at $48.06, while BGLC trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas BGLC's P/E ratio is -2.61. In terms of profitability, GH's ROE is +3.69%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, GH is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs NVTA Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GH is priced at $48.06, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GH's ROE is +3.69%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GH is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs LMDXW Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GH is priced at $48.06, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GH's ROE is +3.69%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs LMDX Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GH is priced at $48.06, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GH's ROE is +3.69%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs CHEK Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, CHEK has a market cap of 4.7M. Regarding current trading prices, GH is priced at $48.06, while CHEK trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas CHEK's P/E ratio is -0.38. In terms of profitability, GH's ROE is +3.69%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, GH is more volatile compared to CHEK. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs TTOO Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, TTOO has a market cap of 4.2M. Regarding current trading prices, GH is priced at $48.06, while TTOO trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas TTOO's P/E ratio is -5.00. In terms of profitability, GH's ROE is +3.69%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, GH is more volatile compared to TTOO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs DMTK Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GH is priced at $48.06, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GH's ROE is +3.69%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, GH is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs ISPC Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, ISPC has a market cap of 3.1M. Regarding current trading prices, GH is priced at $48.06, while ISPC trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas ISPC's P/E ratio is -0.11. In terms of profitability, GH's ROE is +3.69%, compared to ISPC's ROE of -2.39%. Regarding short-term risk, GH is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs BNR Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, BNR has a market cap of 3.1M. Regarding current trading prices, GH is priced at $48.06, while BNR trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas BNR's P/E ratio is -0.62. In terms of profitability, GH's ROE is +3.69%, compared to BNR's ROE of -0.53%. Regarding short-term risk, GH is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs AWH Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, GH is priced at $48.06, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas AWH's P/E ratio is -0.09. In terms of profitability, GH's ROE is +3.69%, compared to AWH's ROE of +4.66%. Regarding short-term risk, GH is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs APDN Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, APDN has a market cap of 2.8M. Regarding current trading prices, GH is priced at $48.06, while APDN trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas APDN's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to APDN's ROE of -2.81%. Regarding short-term risk, GH is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs SQL Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GH is priced at $48.06, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas SQL's P/E ratio is -0.40. In terms of profitability, GH's ROE is +3.69%, compared to SQL's ROE of +10.89%. Regarding short-term risk, GH is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs NDRA Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, NDRA has a market cap of 2.5M. Regarding current trading prices, GH is priced at $48.06, while NDRA trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas NDRA's P/E ratio is 0.01. In terms of profitability, GH's ROE is +3.69%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, GH is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs HTGM Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GH is priced at $48.06, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GH's ROE is +3.69%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GH is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs SQLLW Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, SQLLW has a market cap of 871.8K. Regarding current trading prices, GH is priced at $48.06, while SQLLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas SQLLW's P/E ratio is -0.04. In terms of profitability, GH's ROE is +3.69%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, GH is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs BIOC Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GH is priced at $48.06, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GH's ROE is +3.69%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GH is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs DHR-PA Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GH is priced at $48.06, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GH's ROE is +3.69%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for GH.
GH vs MEUSW Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GH is priced at $48.06, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to MEUSW's ROE of -3.10%. Regarding short-term risk, GH is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.
GH vs OCDX Comparison
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 6B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GH is priced at $48.06, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -14.18, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GH's ROE is +3.69%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GH is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.